

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO. 24945-0026US

In re patent application of:
Hans-Peter BUCHSTALLER et al.

Confirmation No.

Applic. No.: 10/564,185

Art Unit: Unassigned

Filed: January 11, 2006

Examiner: Unassigned

For: BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action that would be appropriate to antedate or otherwise remove as a competent reference any document that is determined to be a *prima facie* prior art reference against the claims of the present application.

RELEVANCE STATEMENT

The foregoing documents came to the Applicant's attention during a search of the corresponding international application. A copy of the International Search Report forth the portion of each reference considered relevant by the examiner is attached.

TIMING/FEEs


The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: April 24, 2006

Heller Ehrman LLP
1717 Rhode Island Avenue, NW
Washington, D.C. 20036
Telephone: (202) 912-2000
Facsimile: (202) 912-2020



Patricia D. Granados
Attorney for Applicant
Reg. No.: 33,683

Customer No. 26633

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|-------------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/564,185 |
| | | | | Filing Date | January 11, 2006 |
| | | | | First Named Inventor | Hans-Peter BUCHSTALLER et al. |
| | | | | Group Art Unit | Unassigned |
| | | | | Examiner Name | Unassigned |
| Sheet | 1 | of | 1 | Attorney Docket Number | 24945-0026US |

| U.S. PATENT DOCUMENTS | | | | | |
|------------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| | A01 | 4,002,623 | 1/11/1977 | Kadin | |
| | A02 | 4,011,236 | 3/8/1977 | Grier | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-------------|---|-----------------------------------|--|--|----------------|
| Examiner Initials* | Cite No. | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | A03 | WIPO 00/27819 | 5/18/2000 | Schering Aktiengesellschaft | | |
| | A04 | WIPO 02/44156 A2 | 6/6/2002 | Glaxo Group Limited | | |
| | A05 | WIPO 03/030902 A1 | 4/17/03 | Tularik Inc. | | |
| | A06 | WIPO 01/21160 A2 | 3/29/2001 | Axxima Pharmaceuticals | | |
| | A07 | WIPO 02/46171 A2 | 6/13/2002 | Signal Pharmaceuticals Inc. | | |
| | A08 | WIPO 2004/001059 A2 | 12/31/2003 | Bristol-Myers Squibb Co. | | |
| | A09 | WIPO 2004/014369 A1 | 2/19/2004 | Aventis Pharma Deutschland GmbH | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

